Aflac Incorporated — Cyborg Score 7/10

Strong
Supplemental Health and Life Insurance

Strategic Profile

The company maintains a record of 43 consecutive years of dividend increases, supported by strong capital and cash flows. Aflac pursues growth through diversifying its product range to meet changing customer needs, with estimated revenue growth of 5-7% annually through 2027.

Cyborg Score Rationale

Aflac reported Q4 2025 revenue of $4.87 billion, up 12.7% year-over-year and exceeding Wall Street estimates by 10.5%. Book value per share grew 22.3% annually over the last two years, though challenged by long-term growth headwinds and recent cybersecurity incident.

Top Insights

  • Japan segment delivered 15.7% sales increase driven by new cancer and medical products
  • Book value per share accelerated to 22.3% annual growth over two years, reaching $56.85 per share
  • 43 consecutive years of dividend increases reflect sustainable capital generation
  • Company addressed network security incident initially disclosed in June 2025

Named Competitors

  • MetLife — Leading insurance company with 12% market share
  • Prudential Financial — Major diversified financial services provider
  • Cigna — Health services and insurance provider

Recent Developments

  • (November 2025) Announced 5.2% dividend increase to $0.61 per share for Q1 2026
  • (February 2026) Reported Q4 2025 results beating revenue expectations with 12.7% year-over-year growth
  • (2025) Launched new cancer and medical insurance products in Japan driving 15.7% sales growth

Open the full interactive Aflac Incorporated report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →